Anti-cancer Drug
China leading manufacturers and suppliers of Anticancer Drug , and we are specialized in Cabozantinib Intermediates, Alectinib Intermediates , Ceritinib Intermediates, Larotrectinib Intermediates, Ponatinib Intermediates , Ruxolitinib Intermediates,Anticancer Drug Development, etc.If you want to buy Anti-cancer Drugs,please contact us.
Cabozantinib, marketed under the trade name Cabometyx among others, is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis. It was discovered and developed by Exelixis Inc.
Cabozantinib will be distributed in Europe by the French pharmaceutical company Ipsen after a collaboration was reached with Exelixis in March of 2016.
Alectinib is a highly selective and potent anaplastic lymphoma kinase (ALK) inhibitor capable of blocking the resistant gatekeeper mutant, which results in reduced cell growth. CH5424802 have been clinically evaluated for the treatment of patients with ALK-driven tumors.
Ceritinib (INN, trade name Zykadia) is a drug for the treatment of a specific type of lung cancer. It is an anaplastic lymphoma kinase (ALK) inhibitor. It was developed by Novartis. It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients that failed treatment with crizotinib. It is a more effective, but more toxic, alternative to traditional platinum-based chemotherapies. Ceritinib was found at physiological concentrations to inhibit ALK, insulin-like growth factor 1 receptor (IGF-1R), and ROS1.
Brigatinib (previously known as AP26113) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc. Brigatinib has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).
Ponatinib (trade name Iclusig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.
Ruxolitinib is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis.
Anticancer Drug Classification,Anticancer Drug List, Cabozantinib Intermediates, Alectinib Intermediates, Ceritinib Intermediates, Larotrectinib Intermediates, Ponatinib Intermediates, Ruxolitinib Intermediates,,Anticancer Drug Development  Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com
At the 2014 Beijing International Road Transport, City Bus and Parts Expo, the American engine manufacturer Cummins launched the first natural gas engine L8.9G developed and produced in China. In the subsequent media exchanges, Peng Lixin, vice president of Cummins, said: "L8.9G is characterized by its cost-effectiveness. Its advantages are high stability, strong dynamics, low gas consumption, and competitive prices."
All parts made in China with an annual output will reach twenty thousand <br> <br> Peng Lixin, said Cummins L8.9G natural gas engines is done by the technical research and development center in Wuhan, the cylinder Cummins diesel engine block provided in Cummins The factory installed Woodward combustion control system to complete the assembly of all parts.
L8.9G adopts the world's advanced natural gas technology R&D platform and CAE simulation simulation tool, which integrates the world's top bench testing equipment and the overall development process has been more than two years. The engine uses the unique domestic real-time analysis of gas components to enable the product to adapt to gas in different regions and has a wide range of applications. L8.9G accumulative bench test verification time exceeds 8000 hours, and in particular carried out severe thermal shock test over 10,000 working cycles, and conducted 600,000 kilometers of actual road operation test for vehicle operating conditions in China market. To ensure reliable operation of the engine under all kinds of operating conditions.
“In the past, natural gas engines were less dynamic than diesel engines. However, according to customer feedback after trial operation, the power of L8.9G is very good, which gives us great confidence.†Peng Lixin.
“The parts of Cummins L8.9G are 100% from China. We can supply small batches in June this year, and we can officially mass-produce them in July, with the capacity to produce 20,000 units per year. Its price is based on the products in the domestic mainstream market. For reference, the price must be competitive with them,†said Peng Lixin. “We hope that the products developed by Wuhan Technology Center in the future will contribute to the application of natural gas engines worldwide.â€
Chinese market increasingly important product will be targeted <br> <br> Cummins is the world's first research and development of gas engine technology enterprise. In the 1960s, natural gas engine research and development began. In the 1980s, Cummins's first natural gas engine for vehicles was very successful once it was launched. At present, Cummins has a total of six R&D centers working together on a global scale to jointly participate in the development of natural gas engines.
In the U.S. market, natural gas engines are widely used. In the bus market, the share of natural gas engines is 15%. In the clean truck market such as sanitation vehicles, the share of natural gas engines reaches 50%, and the share of heavy trucks in long-distance freight transportation is 1%~2%. It is understood that Cummins natural gas engine in the United States natural gas engine market share is 90%.
The use of natural gas vehicles in the Chinese market was relatively early, and it gradually evolved from CNG vehicles to LNG vehicles. In the United States, natural gas for commercial vehicle use is mainly CNG, which is mainly used in short-distance areas. According to Cummins, LNG's market is more promising as more and more large companies use natural gas engines.
Peng Lixin said that China is a country rich in oil, gas, and coal, and there is a great demand for energy. As China adjusts its energy structure, the extraction and import of natural gas is rapidly increasing. With the economic and environmental advantages of natural gas, China is becoming the world's most important natural gas engine market. According to Liu Yue, general manager of the natural gas business in the Asian region of Cummins Asia and the China bus market, in 2013, sales of natural gas trucks sold in China had already exceeded 30,000, and they are still developing at a relatively high rate.
Since 1999, Cummins has launched the Cummins B Series (B5.9G) 195-horsepower and 230-hp Natural Gas Engines (CNG) in the Chinese market, and assisted Beijing Bus to create three “firsts†for natural gas commercial buses. "The number one global gas bus fleet in the city," the "world's largest passenger car" and "the world's largest natural gas bus."
The performance of imported engines is high, but the prices are relatively high, and they cannot fully meet the needs of users. The local bus companies have some special requirements on the dynamic nature, reliability, and environmental performance of vehicles. RoeEast, general manager of Cummins' global medium-heavy gas business, said that it is unrealistic for engineers who are more than 10,000 kilometers away to develop products that are perfectly suited to the Chinese market. Therefore, Cummins needs to do some localized development of products for the Chinese market.